Indrayani Biotech Q1 FY27 Standalone Revenue Rs. 415.34 Lakhs
RESULTS
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 07 Oct 2026, 06:08 PM IST · BSE ID: 21555594-dc7c-42f5-bb07-1b186d1d98d7
View Original BSE Filing (PDF)
💡
In Simple Terms
Indrayani Biotech reported its financial results for the quarter ending June 2026 and announced changes to its board committees.
🤖 AI Summary
- Board approved unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.
- Standalone Revenue from Operations was Rs. 415.34 Lakhs for the quarter ended June 30, 2026.
- Consolidated Revenue from Operations was Rs. 3,770.55 Lakhs for the quarter ended June 30, 2026.
- Profit for the period (Standalone) stood at Rs. 14.50 Lakhs, and Rs. 263.02 Lakhs (Consolidated).
- Company reconstituted its Audit, Stakeholder Relationship, and Rights Issue Committees effectively October 07, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from Operations (Q1 FY27)
415.34 Lakhs
-37.87%
Standalone Profit for the period (Q1 FY27)
14.50 Lakhs
13.55%
Consolidated Revenue from Operations (Q1 FY27)
3,770.55 Lakhs
29.55%
Consolidated Profit for the period (Q1 FY27)
263.02 Lakhs
1580.64%
Standalone Basic EPS (Q1 FY27)
0.03
0.00%
Consolidated Basic EPS (Q1 FY27)
0.58
1833.33%
🏢 How This Affects the Company
The financial results provide an update on the company's revenue generation and operational profitability for the first quarter of FY27, reflecting ongoing business activities.
Standalone profit after tax was Rs. 14.50 Lakhs and consolidated profit after tax was Rs. 263.02 Lakhs for the quarter, impacting the company's overall financial performance.
Reconstitution of committees like Audit, Stakeholder Relationship, and Rights Issue committees reflects adjustments in governance structure.
No specific new risks are introduced by the financial results or committee reconstitutions, with auditors providing an unmodified opinion.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the reported standalone and consolidated revenue and profit figures for the quarter ended June 30, 2026.
🔍
Management Signal
Management is maintaining corporate governance by approving financial results and reconstituting key board committees as per regulatory requirements.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 unaudited financial results — check revenue and profit trends.
Any further updates on the Rights Issue Committee's activities.
Annual General Meeting (AGM) announcements for management decisions.
MEDIUM RISK
Standalone revenue decline and significant consolidated profit increase warrant closer monitoring for sustainability and underlying drivers.
💡 Investor Takeaway
Indrayani Biotech reported Q1 FY27 unaudited consolidated revenue from operations of Rs. 3,770.55 Lakhs, a 29.55% YoY increase from Rs. 2,910.37 Lakhs in Q1 FY26. Consolidated profit for the period was Rs. 263.02 Lakhs, up significantly from Rs. 15.65 Lakhs YoY. Standalone revenue decreased 37.87% YoY.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Revenue from Operations increased to Rs. 3,770.55 Lakhs for Q1 FY27 from Rs. 2,910.37 Lakhs in Q1 FY26.
- Consolidated Profit for the period significantly increased to Rs. 263.02 Lakhs in Q1 FY27 from Rs. 15.65 Lakhs in Q1 FY26.
⚠️ Concerns
- Standalone Revenue from Operations decreased to Rs. 415.34 Lakhs for Q1 FY27 from Rs. 668.57 Lakhs in Q1 FY26.
- Standalone Employee Benefit Expense remained substantial at Rs. 100.60 Lakhs for Q1 FY27, constituting a significant portion of expenses.
📅 Company Track Record
No previous filings or specific historical financial data for Indrayani Biotech Ltd. (BSE: 526445) were provided in the past filings context to establish a trend for comparison beyond the available quarterly data in this filing.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Indrayani Biotech's consolidated revenue from operations for Q1 FY27?
Indrayani Biotech reported consolidated revenue from operations of Rs. 3,770.55 Lakhs for the quarter ended June 30, 2026.
What was Indrayani Biotech's consolidated profit for the period in Q1 FY27?
The consolidated profit for the period for Indrayani Biotech was Rs. 263.02 Lakhs for the quarter ended June 30, 2026.
What was Indrayani Biotech's standalone revenue from operations for Q1 FY27?
Indrayani Biotech reported standalone revenue from operations of Rs. 415.34 Lakhs for the quarter ended June 30, 2026.
Which committees of Indrayani Biotech's Board were reconstituted on October 07, 2026?
The Audit Committee, Stakeholder Relationship Committee, and Rights Issue Committee of Indrayani Biotech's Board were reconstituted on October 07, 2026.
What was the consolidated basic EPS for Indrayani Biotech in Q1 FY27?
The consolidated basic Earnings Per Share (EPS) for Indrayani Biotech was Rs. 0.58 for the quarter ended June 30, 2026.
Questions based on this BSE filing only. For information purposes.